Long-term outcomes of intraoperative and perioperative albendazole treatment in hepatic hydatidosis: single center experience
Annals of Surgical Treatment and Research
;
: 61-65, 2014.
Artículo
en Inglés
| WPRIM
| ID: wpr-193663
ABSTRACT
PURPOSE:
The aim of this study was to evaluate long-term outcome of the intraoperative and perioperative albendazole (ALB) treatment on the recurrence and/or secondary hydatidosis.METHODS:
One hundred and one patients with hepatic hydatidosis were treated intraoperatively and perioperatively with ALB, in addition to surgery. Perioperative ALB treatment was given in a dose of 12-15 mg/kg/day. The ALB treatment was started 13.27 +/- 14.34 days before the surgery, and it was continued for 4.39 +/- 3.11 months postoperatively. A total of 1.7 microg/mL of ALB solution was used as a protoscolidal agent. The follow-up period was 134.55 +/- 51.56 months.RESULTS:
Four patients died, with only one death was secondary to hydatid disease (cerebral eccinococcus). There was only one recurrence (1%) of hepatic hydatidosis. Early and late morbidity rates were 8.91% and 7.92%, respectively.CONCLUSION:
Our results suggest that intraoperative and perioperative ALB is effective for the prevention of hepatic hydatidosis recurrence and/or secondary hydatidosis.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Recurrencia
/
Albendazol
/
Estudios de Seguimiento
/
Equinococosis
/
Equinococosis Hepática
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Annals of Surgical Treatment and Research
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS